# EDGAR Filing Document

**Accession Number:** 0001527753
**File Stem:** 0001193125-25-173575
**Filing Date:** 2025-8
**Character Count:** 23179
**Document Hash:** 63fa566c264bbc88e661d86f1c1edaeb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-173575.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001193125-25-173575

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250805

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Personalis, Inc.
- **CENTRAL INDEX KEY:** 0001527753
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 275411038
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38943
- **FILM NUMBER:** 251185609

**BUSINESS ADDRESS:**
- **STREET 1:** 6600 DUMBARTON CIRCLE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94555
- **BUSINESS PHONE:** 650-752-1300

**MAIL ADDRESS:**
- **STREET 1:** 6600 DUMBARTON CIRCLE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94555

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): August 5, 2025

## Personalis, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38943** | **27-5411038** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **6600 Dumbarton Circle**<br> **Fremont, California** | **94555** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

(650) 752-1300

#### Registrant's Telephone Number, Including Area Code

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0001 par value per share | PSNL | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On August 5, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 99.1 | [Press release of Personalis, Inc., dated August 5, 2025.](d64395dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 5, 2025 | Personalis, Inc. | Personalis, Inc. |
|  | By: | /s/ Aaron Tachibana |
|  |  | Aaron Tachibana |
|  |  | Chief Financial Officer and Chief Operating Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g64395g0806010929971.jpg)

**Personalis Reports Second Quarter 2025 Financial Results** 

*Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume* 

**FREMONT, Calif. – August 5, 2025 –** Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy:

**Second Quarter 2025 and Recent Business Highlights** 

• Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase
over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal<sup>®</sup> platform

• Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc. (Tempus) to add
colorectal cancer, a major new indication, to the exclusive commercialization agreement, positioning Personalis to win in this attractive market

• World-Class Clinical Evidence Generation: Presented pivotal data at the 2025 ASCO Annual Meeting, including
results from the PREDICT and SCANDARE studies showing NeXT Personal's ability to predict therapy response in breast cancer. Notably, nearly half of all positive detections were found in the ultra-sensitive range

• Clinical Utility Demonstration: Additional data presented at ASCO from the Phase 3 CALLA trial in partnership
with AstraZeneca showed NeXT Personal detected cervical cancer progression up to 16 months earlier than standard imaging

"The results of our "Win-in-MRD" strategy are clear, with an impressive 59% sequential growth in our clinical test volume," said Chris Hall, Chief Executive Officer and President of Personalis. "This powerful adoption trend is fueled by a continuous flow of compelling clinical data, like our recent landmark ASCO presentations, which prove the unique value of our ultra-sensitive MRD platform in guiding patient care. Steady recognition and growth in the use of our platform continues to support our strategy as we navigate the temporary headwinds in the biopharma sector which have affected our current results. Our fundamental growth engine is accelerating, keeping us firmly on track to achieve our most critical strategic objectives for 2025, including securing Medicare coverage for two indications."

**Second Quarter 2025 Financial Results Compared with 2024** 

• Revenue of $17.2 million for the second quarter of 2025 compared with $22.6 million, a decrease of 24%,
primarily due to the expected decline of $5.6 million in revenue from Natera, and a decrease in revenue from pharma tests and services, and other customers of $2.1 million, partially offset by an increase in population sequencing revenue
of $2.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pharma tests and services, and other customers of $11.1 million for the second quarter of 2025 compared with
$13.2 million, a decrease of 16%

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Population sequencing of $3.3 million for the second quarter of 2025 compared with $1.3 million, an
increase of 158%

• Gross margin of 27.6% for the second quarter of 2025 compared with 35.6%, a decrease of 8.0% primarily due to
lower revenue volume, customer mix, and increased unreimbursed clinical test costs

• Net loss of $20.1 million, and net loss per share of $0.23 based on a weighted-average basic and diluted
share count of 88.5 million in the second quarter 2025, compared with a net loss of $12.8 million, and net loss per share of $0.24 based on a weighted-average basic and diluted share count of 52.4 million

• Cash, cash equivalents, and short-term investments of $173.2 million as of June 30, 2025; cash usage of
$13.2 million from operations and capital equipment additions in the second quarter of 2025

**Third Quarter and Full Year 2025 Outlook** 

Personalis expects the following for the third quarter of 2025:

• Total company revenue to be in the range of $12.0 to $14.0 million

• Revenue from pharma tests and services, and all other customers to be in the range of $11.0 to $13.0 million

• Revenue from population sequencing and enterprise sales of approximately $1.0 million

Personalis now expects the following for the full year of 2025 (updated guidance):

• Total company revenue in the range of $70 to $80 million (reduced from $80 to $90 million)

• Revenue from pharma tests and services, and all other customers in the range of $52 to $58 million (reduced
from $62 to $64 million); the lower range is due to variability with biopharma projects and timing of sample receipts

• Revenue from population sequencing and enterprise sales in the range of $15 to $16 million

• Revenue from clinical tests reimbursed in the range of $3 to $6 million (narrowed range from $3 to $10
million)

• Gross margin in the range of 22% to 24%, which is lower than the 32% gross margin for the full year of 2024 as we
invest to drive clinical use of NeXT Personal ahead of reimbursement

• Net loss of approximately $85 million (increased from $83 million)

• Cash usage of approximately $75 million, which is an increase from the $47 million used in the full
year of 2024 primarily due to investments in the next phase of our "Win-in-MRD" strategy, including growing test volume, expanding clinical evidence
generation, and investing in commercial capabilities to drive growth

**Webcast and Conference Call Information** 

Personalis will host a conference call to discuss the second quarter financial results, as well as plans for 2025, after market close on Tuesday, August 5, 2025, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar can be accessed at https://investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

**About Personalis, Inc.** 

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit <u>www.personalis.com</u> and connect with us on <u>LinkedIn</u> and X (<u>Twitter</u>).

------

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "anticipate," "estimate," "expect," "if," "may," "future," "will," "position" or similar expressions. These statements include statements relating to: Personalis' achievement of its most critical strategic objectives for 2025, including receipt of Medicare reimbursement coverage for two indications, and Personalis' third quarter and full year 2025 financial guidance. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from ModernaTX, Inc., Merck Sharp & Dohme LLC and Natera, Inc.; our revenue guidance assumes the receipt of a task order from the U.S. Department of Veterans Affairs' Million Veteran Program in September in line with previous years, but there is no assurance that we will receive such a task order on the timeframe or in the amount we expect, or at all; the timing of tissue, blood, and other specimen sample receipts from customers, including from our biopharma customers for their clinical trials, which materially impacts revenue quarter-over-quarter and year-over-year; the success of Personalis' clinical sales team's and Tempus' sales and marketing efforts; Personalis' ability to demonstrate attributes, advantages or clinical validity of the NeXT platform, including the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultra-sensitive range; future clinical data differing from the clinical data previously presented or expected results; the rate of adoption and use of the NeXT platform, including maintaining the accelerated physician adoption rates experienced in the second quarter of 2025; building our clinical laboratory business is subject to a number of reimbursement challenges and we may not be able to establish the medical necessity of our tests for coverage or reimbursement rates that cover our costs on the timelines expected, or at all; if we do not secure Medicare reimbursement coverage for two indications this year or if the reimbursement coverage occurs later in the year than expected, we will not or may not, respectively, be able to achieve our revenue guidance from clinical tests, in which case our ability to achieve our overall revenue guidance would also be negatively impacted; the impact of competition and macroeconomic factors on our business; the partnering and/or collaboration arrangements that we have entered into or may enter into in the future may not be successful, or may terminate, which could adversely impact our business or affect our ability to develop and commercialize our services and products; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, being filed with the SEC later today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

**Contacts:** 

Investor Relations Contact:

Caroline Corner

investors@personalis.com

415-202-5678

Media:

pr@personalis.com

------

**PERSONALIS, INC.** 

**CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)** 

(In thousands, except share and per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  Revenue <sup>(1)</sup> | $17203 | $22580 | $37808 | $42105 |
|  Costs and expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of revenue | 12447 | 14543 | 25845 | 28575 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development | 12381 | 12957 | 25021 | 25728 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selling, general and administrative <sup>(2)</sup> | 14179 | 11973 | 26442 | 23575 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total costs and expenses | 39007 | 39473 | 77308 | 77878 |
|  Loss from operations | (21804) | (16893) | (39500) | (35773) |
|  Interest income | 1878 | 1136 | 3905 | 2495 |
|  Interest expense | (48) | (9) | (76) | (18) |
|  Other income (expense), net | (80) | 2968 | (126) | 7537 |
|  Loss before income taxes | (20054) | (12798) | (35797) | (25759) |
|  Provision for income taxes | 2 | 4 | 9 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss | $(20056) | $(12802) | $(35806) | $(25770) |
|  Net loss per share, basic and diluted | $(0.23) | $(0.24) | $(0.41) | $(0.50) |
|  Weighted-average shares outstanding, basic and diluted | 88517498 | 52394678 | 87990691 | 51536632 |

---

(1) Includes related party revenue of $1.9 million and $2.4 million for the three and six months ended
June 30, 2025, respectively.

(2) Includes related party sales and marketing expenses of $0.9 million and $1.5 million for the three
and six months ended June 30, 2025, respectively.

------

**PERSONALIS, INC.** 

**SUPPLEMENTAL REVENUE INFORMATION (Unaudited)** 

(In thousands)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  Pharma tests and services <sup>(1)</sup> | $11023 | $13197 | $24617 | $23009 |
|  Enterprise sales | 2315 | 7958 | 4780 | 15930 |
|  Population sequencing | 3308 | 1280 | 7521 | 2780 |
|  Clinical diagnostic | 469 | 117 | 777 | 312 |
|  Other | 88 | 28 | 113 | 74 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenue | $17203 | $22580 | $37808 | $42105 |

---

(1) Includes related party revenue of $1.9 million and $2.4 million for the three and six months ended
June 30, 2025, respectively.

------

**PERSONALIS, INC.** 

**CONSOLIDATED BALANCE SHEETS (Unaudited)** 

(In thousands, except share and par value data)

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  **Assets** |  |  |
|  Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $53374 | $91415 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term investments | 119858 | 93594 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable, net <sup>(1)</sup> | 9952 | 8140 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventory and other deferred costs | 5435 | 5939 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | 4724 | 3927 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 193343 | 203015 |
|  Property and equipment, net | 45812 | 48274 |
|  Operating lease right-of-use assets | 15654 | 16453 |
|  Other long-term assets | 3871 | 2526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $258680 | $270268 |
|  **Liabilities and Stockholders' Equity** |  |  |
|  Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable <sup>(2)</sup> | $9926 | $6397 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued and other current liabilities <sup>(2)</sup> | 20172 | 21629 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contract liabilities | 1625 | 3100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 31723 | 31126 |
|  Long-term operating lease liabilities | 33390 | 34882 |
|  Other long-term liabilities <sup>(3)</sup> | 2738 | 1303 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 67851 | 67311 |
|  Commitments and contingencies (Note 11) |  |  |
|  Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common stock, $0.0001 par value — 200,000,000 shares authorized; 88,649,766 and 85,171,146 shares issued and outstanding, respectively | 9 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional paid-in capital | 776596 | 752961 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated other comprehensive income (loss) | 20 | (23) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated deficit | (585796) | (549990) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 190829 | 202957 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $258680 | $270268 |

---

(1) Includes related party accounts receivable of $1.9 million and $2.5 million as of June 30, 2025
and December 31, 2024, respectively.

(2) Includes related party liabilities of $3.7 million and $1.7 million as of June 30, 2025 and
December 31, 2024, respectively.

(3) Includes related party liabilities of $1.1 million and $1.2 million as of June 30, 2025 and
December 31, 2024, respectively.